4df6c488-ef2f-4019-a1b0-3a3624039be8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- APICAL_SURFACE+0.440
- CHOLESTEROL_HOMEOSTASIS+0.400
- MYOGENESIS+0.400
- ANGIOGENESIS+0.390
- APICAL_JUNCTION+0.330
- UV_RESPONSE_DN+0.320
- ESTROGEN_RESPONSE_EARLY+0.310
- TGF_BETA_SIGNALING+0.310
- COAGULATION+0.290
Top 10 suppressed
- E2F_TARGETS-0.490
- INTERFERON_ALPHA_RESPONSE-0.480
- MYC_TARGETS_V1-0.390
- G2M_CHECKPOINT-0.370
- INTERFERON_GAMMA_RESPONSE-0.370
- MYC_TARGETS_V2-0.360
- TNFA_SIGNALING_VIA_NFKB-0.280
- MITOTIC_SPINDLE-0.240
- DNA_REPAIR-0.210
- ALLOGRAFT_REJECTION-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20040084.LumA | — | A | 0.900 |
| 2 | TCGA-A8-A06P-01A-11R-A00Z-07 | — | A | 0.898 |
| 3 | TCGA-CV-7177-01A-11R-2016-07 | — | — | 0.870 |
| 4 | SRR8613707 | — | C | 0.850 |
| 5 | 20050118.TNBC | — | F | 0.840 |
| 6 | SRR8518453 | — | F | 0.826 |
| 7 | SRR8613710 | — | F | 0.824 |
| 8 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.821 |
| 9 | 20020054.LumA | — | A | 0.818 |
| 10 | 20060030.TNBC | — | F | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.440 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |